P&G acquires Thorne for $3.8bn, signalling shift to performance-driven supplements
Procter & Gamble's acquisition of Thorne for $3.8 billion underscores a strategic pivot towards science-backed, performance-oriented dietary supplements, reflecting changing consumer demographics and premiumisation within the wellness sector.
London, United Kingdom — 04 August 2026
Procter & Gamble (P&G) has announced its intention to acquire Thorne, a prominent dietary supplement manufacturer, from L Catterton’s Flagship Fund for $3.8 billion. This significant transaction signals a strategic expansion for P&G into the premium, science-backed wellness category, directly targeting the evolving demands of younger consumers. Thorne, reporting over $500 million in annual revenue, has successfully repositioned its brand to appeal to Millennials and Gen Z, focusing on performance-oriented and personalised health solutions rather than traditional broad-spectrum supplements.
The acquisition reflects a broader industry trend where private equity-backed firms are driving innovation and market capture through product differentiation and targeted consumer engagement. Thorne's growth under L Catterton demonstrates the commercial viability of investing in robust scientific validation and catering to specific demographic cohorts. For brand owners and manufacturers, P&G’s entry into this segment with a high-value acquisition like Thorne necessitates a re-evaluation of product portfolios and marketing strategies to remain competitive.
The move by a consumer goods giant like P&G into advanced nutritional products underscores the increasing mainstream acceptance and demand for sophisticated supplement formulations. This can lead to greater R&D investment across the industry, but also pressure on smaller players to differentiate or risk market consolidation. The transaction, pending regulatory approvals, is expected to close later this year, setting a new benchmark for valuations in the science-backed supplement space.
What this means for United Kingdom
UK supplement manufacturers and brand owners face intensified competition in the premium and personalised nutrition segments. P&G's entry via Thorne will likely drive up marketing spend and consumer expectations for science-backed efficacy, compressing margins for brands unable to demonstrate clear value. Brands must reassess their ingredient sourcing and claims substantiation to meet potential higher regulatory scrutiny and consumer demand for transparency. Reformulation windows for existing product lines should be prioritised to incorporate performance-oriented ingredients and attract younger demographics, aligning with Thorne's successful strategy. Procurement leads should anticipate potential raw material price increases as large players like P&G enter this competitive space.
The acquisition of Thorne by P&G signifies a pivotal moment for the supplement industry, highlighting the growing importance of scientific validation and targeted consumer engagement. Brands must adapt swiftly to these shifts or risk losing market share to better-resourced competitors.
For more on UK formulation and manufacturing best practice, learn more at Supplement Factory.